Jazz Pharmaceuticals PLC (JAZZ) - What Are Analysts Thinking About This Stock?

Key Points

• Analysts are broadly positive: Jazz Pharmaceuticals has a “Moderate Buy” consensus from 20 firms, with 18 buy or strong-buy ratings and an average 12-month price target of $293.45.
• Quarterly results topped expectations: Revenue was $1.24 billion, up 10.4% year over year, and EPS beat estimates. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion.
• Several insiders sold shares, including transactions under pre-arranged Rule 10b5-1 plans; institutional investors own 89.14% of the stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $293.45.

JAZZ has been the subject of a number of recent analyst reports. Barclays upped their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a research report on Tuesday, November 3rd. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 3rd. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $337.00 price objective on the stock. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an "outperform" rating in a research note on Tuesday, August 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a research note on Wednesday, August 26th.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,413 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer owned 6,512 shares of the company's stock, valued at approximately $1,506,616.32. The trade was a 17.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the sale, the director directly owned 351,875 shares in the company, valued at $88,014,493.75. The trade was a 1.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 102,534 shares of company stock worth $25,185,243. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Triumph Capital Management raised its stake in Jazz Pharmaceuticals by 2.0% during the second quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company's stock valued at $626,000 after buying an additional 52 shares during the last quarter. Keybank National Association OH increased its holdings in shares of Jazz Pharmaceuticals by 0.6% during the third quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company's stock valued at $2,348,000 after acquiring an additional 57 shares in the last quarter. XML Financial LLC raised its position in shares of Jazz Pharmaceuticals by 1.1% in the 3rd quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company's stock worth $1,519,000 after purchasing an additional 71 shares during the last quarter. Bessemer Group Inc. grew its position in Jazz Pharmaceuticals by 0.3% during the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock valued at $4,228,000 after purchasing an additional 73 shares during the last quarter. Finally, Evergreen Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 4.2% in the third quarter. Evergreen Capital Management LLC now owns 2,250 shares of the specialty pharmaceutical company's stock worth $521,000 after buying an additional 90 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $234.76 on Monday. The firm has a market cap of $15.07 billion, a PE ratio of 79.85, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. Jazz Pharmaceuticals has a 12-month low of $128.80 and a 12-month high of $266.38. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The company's fifty day simple moving average is $229.39 and its two-hundred day simple moving average is $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.13 earnings per share. As a group, equities analysts expect that Jazz Pharmaceuticals will post 11.08 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.